Accuray Incorporated (ARAY)
| Market Cap | 11.72M -92.9% |
| Revenue (ttm) | 394.53M -12.5% |
| Net Income | -17.38M |
| EPS | -5.66 |
| Shares Out | 2.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 185,050 |
| Open | 4.000 |
| Previous Close | 4.400 |
| Day's Range | 3.550 - 4.050 |
| 52-Week Range | 3.550 - 48.400 |
| Beta | 1.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About ARAY
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidn... [Read more]
Financial Performance
In fiscal year 2026, Accuray's revenue was $401.95 million, a decrease of -12.34% compared to the previous year's $458.51 million. Losses were -$49.19 million, 2992.0% more than in 2025.
Financial StatementsNews
Accuray trading halted, news pending
19:50 EST Accuray (ARAY) trading halted, news pending
Accuray announces 1-for-40 reverse stock split
Accuray (ARAY) announced that its Board of Directors has approved a 1-for-40 reverse stock split of the company’s common stock and a corresponding decrease to the authorized number of shares…
Accuray reports Q3 EPS (10c) ex-items vs. (18c) last year
Reports Q3 revenue $86.52M vs. $93.94M last year. “FY26 was a year of transformation, and FY27 is about execution,” said CEO Steve La Neve. “During Q1, we made progress across…
Accuray Earnings Call Transcript: Q1 2027
FY27 Q1 revenue fell 8% YoY as product revenue dropped 26%, partly offset by 4% service growth and improving service margins. Adjusted EBITDA turned positive at $2.5M, while commercial execution and product volume remain key priorities.
Accuray Earnings release: Q1 2027
Accuray released its Q1 2027 earnings on November 4, 2026, summarizing the period's financial results.
Accuray Slides: Q1 2027
Accuray has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on November 4, 2026.
Accuray Quarterly report: Q1 2027
Accuray has published its Q1 2027 quarterly earnings report on November 4, 2026.
Accuray Announces 1-for-40 Reverse Stock Split
MADISON, Wis., Nov. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its Board of Directors has approved a 1-for-40 reverse stock split of the Company's common stock an...
Accuray Reports Fiscal 2027 First Quarter Financial Results
MADISON, Wis., Nov. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2026.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis., Oct. 30, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Sofiane Laoussadi, the company's new S...
Accuray to Report First Quarter Fiscal 2027 Financial Results on November 4, 2026
MADISON, Wis., Oct. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2027, ended September 30, 2026, during a conference ...
Accuray Proxy statement: Proxy filing
Accuray filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Accuray appoints Richard Meier to board of directors
Accuray (ARAY) announced that Richard A. Meier has been appointed as a member of Accuray’s board of directors, effective immediately, and will serve on the company’s Compensation Committee. Meier brin...
Accuray stockholders approves transactions with TCW Asset Management Company
Accuray (ARAY) Incorporated announced that stockholders approved all proposals presented at the company’s Special Meeting of Stockholders held on October 6, enabling Accuray to complete its previously...
Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director
MADISON, Wis., Oct. 6, 2026 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced that stockholders approved all proposals presented at the company's Special Meeting of Stockholders held...
Accuray Transcript: EGM 2026
Stockholders approved preferred-stock conversion-related share issuance, doubling authorized common shares to 400 million, and a board-discretionary 1-for-15 to 1-for-40 reverse split to address Nasdaq bid-price compliance. Final results were due on Form 8-K within four business days.
Why is Accuray Incorporated Stock (ARAY) Up 60% Today?
Accuray Incorporated ($ARAY) shares rocketed nearly 60% in pre-market trading today after it struck an agreement with Samsung America ($SSNLF) to boost its cancer-fighting CyberKnife technology with n...
Accuray, Samsung NeuroLogica advance volumetric imaging collaboration
Accuray Incorporated (ARAY) announced that it had entered into agreements with Samsung HME America (SSNLF) to pursue advanced volumetric imaging capabilities for the CyberKnife System. The announcemen...
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
MADISON, Wis., Sept. 27, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung Ne...
Accuray Proxy statement: Proxy filing
Accuray filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today anno...
Accuray Registration statement: Registration filing
Accuray filed a registration statement on September 9, 2026, providing details about a securities offering with the SEC.
Accuray Proxy statement: Proxy filing
Accuray filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Accuray Registration statement: Registration filing
Accuray filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Accuray Earnings Call Transcript: Q4 2026
Fiscal 2026 saw significant transformation, with strengthened financials, improved service margins, and new strategic partnerships, despite revenue declines driven by lower product sales and macroeconomic headwinds. The TCW transaction enhances liquidity and flexibility for future growth.